GSA Capital Partners’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-41,682
| Closed | -$380K | – | 2040 |
|
|
2025
Q2 | $380K | Sell |
41,682
-26,064
| -38% | -$192K | 0.03% | 1116 |
|
|
2025
Q1 | $539K | Buy |
67,746
+50,072
| +283% | +$367K | 0.05% | 758 |
|
|
2024
Q4 | $96K | Buy |
+17,674
| New | +$108K | 0.01% | 1513 |
|
|
2024
Q3 | – | Sell |
-78,749
| Closed | -$855K | – | 1963 |
|
|
2024
Q2 | $855K | Buy |
78,749
+67,094
| +576% | +$860K | 0.06% | 610 |
|
|
2024
Q1 | $218K | Sell |
11,655
-58,724
| -83% | -$1.35M | 0.02% | 1374 |
|
|
2023
Q4 | $1.52M | Buy |
+70,379
| New | +$1.39M | 0.13% | 215 |
|
|
2023
Q2 | – | Sell |
-10,721
| Closed | -$450K | – | 1892 |
|
|
2023
Q1 | $450K | Buy |
+10,721
| New | +$461K | 0.04% | 780 |
|
|
2022
Q4 | – | Sell |
-13,557
| Closed | -$531K | – | 1833 |
|
|
2022
Q3 | $531K | Sell |
13,557
-5,193
| -28% | -$201K | 0.07% | 524 |
|
|
2022
Q2 | $606K | Buy |
+18,750
| New | +$628K | 0.09% | 377 |
|
|
2022
Q1 | – | Sell |
-26,035
| Closed | -$1.11M | – | 1786 |
|
|
2021
Q4 | $1.11M | Buy |
26,035
+17,664
| +211% | +$740K | 0.14% | 163 |
|
|
2021
Q3 | $371K | Sell |
8,371
-9,010
| -52% | -$413K | 0.04% | 882 |
|
|
2021
Q2 | $987K | Buy |
+17,381
| New | +$1.23M | 0.11% | 264 |
|
|
2021
Q1 | – | Sell |
-6,487
| Closed | -$561K | – | 1441 |
|
|
2020
Q4 | $561K | Buy |
6,487
+1,743
| +37% | +$128K | 0.09% | 359 |
|
|
2020
Q3 | $290K | Buy |
+4,744
| New | +$240K | 0.05% | 764 |
|
|
2020
Q2 | – | Sell |
-21,374
| Closed | -$614K | – | 1046 |
|
|
2020
Q1 | $614K | Buy |
21,374
+15,207
| +247% | +$881K | 0.15% | 86 |
|
|
2019
Q4 | $445K | Buy |
+6,167
| New | +$759K | 0.05% | 737 |
|
|
2015
Q3 | – | Sell |
-5,600
| Closed | -$409K | – | 1989 |
|
|
2015
Q2 | $409K | Buy |
+5,600
| New | +$360K | 0.02% | 1463 |
|
Other funds holding SAGE
IA
HNB
GSA Capital Partners's SAGE Position: Q3 2025 in Review
GSA Capital Partners sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 41,682 shares — an estimated $380K sold.
GSA Capital Partners first reported a position in SAGE in Q2 2015 and held it in 17 quarters. The position peaked at $1.52M in Q4 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- GSA Capital Partners reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- GSA Capital Partners sold 41,682 Sage Therapeutics shares in Q3 2025, an estimated $380K.
- GSA Capital Partners first reported a position in Sage Therapeutics in Q2 2015 and held it in 17 quarters.
- GSA Capital Partners's Sage Therapeutics position peaked at $1.52M in Q4 2023.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.